| Application no. and date | 17751954.3 (espacenet) (Federated) (European Patent Register), 20170803 | | Patent/reg. no. and date | DK/EP 3494108, 20201028 | | Publication date | 20190612 | | Priority no. and date | US 201662371686 P, 20160805, US 201762536862 P, 20170725 | | EP pub. no. and date |
EP 3494108 20190612 | | Effective date | | | Applicant/owner | Amgen Inc., One Amgen Center Drive
Thousand Oaks, California 91320, US | | Applicant ref. no. | 1579140 | | Inventor | CUI, Sheng, 391 Lincoln Street
Lexington, Massachusetts 02421, US,
SHI, Xianqing, 477 Fallbrook Avenue
Newbury Park, California 91320, US,
BEAVER, Matthew, 50 Park Avenue
Natick, Massachusetts 01760, US | | Representative | RWS Group, RWS Compass House
Vanwall Business Park, Vanwall Road
Maidenhead, Berkshire
SL6 4UB, GB | | Opponent | | | IPC Class | C01G 45/00 (2006.01) , C07D 303/36 (2006.01) | | Title | SYNTESE AF (S)-2-AMINO-4-METHYL-1-((R)-2-METHYLOXIRAN-2-YL)-PENTAN-1-ON OG FARMACEUTISK ACCEPTABLE SALTE DERAF | | Int. application no. | US2017045274 | | Int. publication no. | WO2018027021 | | Related patent (certificate) | | | Status | DK/EP patent | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
